B cell malignancies
Clinical trials for B cell malignancies explained in plain language.
Never miss a new study
Get alerted when new B cell malignancies trials appear
Sign up with your email to follow new studies for B cell malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Off-the-Shelf CAR t cells take on tough blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and…
Matched conditions: B CELL MALIGNANCIES
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Double-Pronged immune cells take aim at blood cancers
Disease control Not yet recruitingThis study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD22, on the surface of B cell cancer cells. The treatment involves infusing these engineered immune cells into patients whose B cell malignancies have returned or not r…
Matched conditions: B CELL MALIGNANCIES
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis trial tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD70, found on certain B cell cancers. The treatment involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing …
Matched conditions: B CELL MALIGNANCIES
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New CAR-T therapy aims to tackle tough blood cancers
Disease control Not yet recruitingThis trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…
Matched conditions: B CELL MALIGNANCIES
Phase 1/2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
MRNA cancer therapy takes on tough B-Cell tumors
Disease control Not yet recruitingThis early-phase trial tests a new mRNA drug called WGb-0301 in 9 patients with B-cell cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. The drug uses lipid nanoparticles to deliver mRNA that targets a protein called CD19 on cancer cells.…
Matched conditions: B CELL MALIGNANCIES
Early phase 1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New CAR t therapy targets two proteins to fight blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safe…
Matched conditions: B CELL MALIGNANCIES
Phase 1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Scientists hunt for immune weak spots in B-Cell cancers
Knowledge-focused Not yet recruitingThis study looks at two immune-related proteins, CD274 and CD276, in people newly diagnosed with B-cell cancers like leukemia and lymphoma. Researchers will use a blood test to measure these proteins and see how they help cancer hide from the immune system. The goal is to find be…
Matched conditions: B CELL MALIGNANCIES
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New immune clues could unlock better b-cell cancer treatments
Knowledge-focused Not yet recruitingThis study will measure two immune system markers, CD305 and CD85d, on cancer cells from 180 people newly diagnosed with B-cell blood cancers. The goal is to see how these markers relate to different cancer types and patient outcomes. No treatment is given; the study only observe…
Matched conditions: B CELL MALIGNANCIES
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC